Part this study presented in poster format at the ECCO-ESMO Multidisciplinary Cancer Congress, 23–27 September 2011, Stockholm, Sweden.
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin
Article first published online: 10 JAN 2013
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society
British Journal of Clinical Pharmacology
Volume 75, Issue 2, pages 507–521, February 2013
How to Cite
Devriese, L. A., Witteveen, P. O., Wanders, J., Law, K., Edwards, G., Reyderman, L., Copalu, W., Peng, F., Marchetti, S., Beijnen, J. H., Huitema, A. D. R., Voest, E. E. and Schellens, J. H. M. (2013), Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. British Journal of Clinical Pharmacology, 75: 507–521. doi: 10.1111/j.1365-2125.2012.04381.x
- Issue published online: 10 JAN 2013
- Article first published online: 10 JAN 2013
- Accepted manuscript online: 16 JUL 2012 09:39AM EST
- Manuscript Accepted: 23 JUN 2012
- Manuscript Received: 26 JAN 2012
- Eisai Inc
- 1Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38: 504–513., , , , , .
- 10U.S.National Institute of Health. Available at http://www.clinicaltrials.gov (last accessed 26 April 2011).
- 15European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Note for guidance on the investigation of drug interactions. 17-12-1997. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002966.pdf (last accessed 2 August 2012).
- 16U.S. Food and Drug Administration. Guidance for industry drug interaction studies – study design, data analysis, and implications for dosing and labeling. 2006. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM0292362.pdf (last accessed 2 August 2012).
- 19Summary of products characteristics for Halaven. 2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002084/WC500105112.pdf (last accessed 2 August 2012).
- 20European Clinical Trials Database. Available at https://eudract.ema.europa.eu/ (last accessed 18 May 2012).
- 21Summary of products characteristics for Rifadin. 2010. Available at http://www.medicines.org.uk/EMC/medicine/21223/SPC/Rifadin+300mg+Capsules/ (last accessed 2 August 2012).
- 22Cancer Therapy Evaluation Program NCI Common Terminology Criteria AE Version 3.0 (NCI-CTCAE v3.0). 2006.
- 23New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216., , , , , , , , , .
- 27Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Invest New Drugs 2012. Epub May 5; doi: s10637-012-9829-3., , , , , , , , , , .